For NSCLC patients with mutant TP53 and wild‐type RTK, anti‐PD‐1/PD‐L1 is a good choice, because TP53‐mutated tumours were characterized by higher PD‐L1 expression and more potent immunogenicity, which means better response to checkpoint inhibitor.10, 11. The gene discussed is TP53; the disease is non-small cell lung carcinoma.